SABCS: AZ writes the 'next chapter' in Enhertu's saga with head-to-head win versus Roche's Kadcyla

As AstraZeneca and Daiichi Sankyo seek to rewrite the breast cancer playbook—and dethrone Roche’s MVP Kadcyla—the question is becoming not who should get the partners’ Enhertu, but who shouldn’t.

That’s according to Dave Fredrickson, executive vice president of AstraZeneca’s oncology business unit, who recently sat down with Fierce Pharma to discuss the antibody-drug conjugate’s “game-changing” readouts at this year’s meeting of the San Antonio Breast Cancer Symposium (SABCS).